SuzhouJune 22, 2026 /PRNewswire/ — From June 11 to 14, 2026, the ISMIO 2026 International Society for Multidisciplinary Interventional Oncology Annual Meeting, jointly held with the 20th Annual Meeting of the Asia-Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR), took place in Suzhou. As a significant international academic conference in the fields of interventional oncology and interventional radiology, the event brought together clinical experts, research scholars, and industry representatives from both domestic and international backgrounds to discuss technological innovations and development trends in interventional diagnosis and treatment.
During the conference, Zhuhai Hengle Medical Technology Co., Ltd. hosted a satellite symposium titled “Innovative Advances in Percutaneous Interventional Surgical Robots.” The conference chair, Academician Teng Gaojun of the Chinese Academy of Sciences and Zhongda Hospital Southeast University, attended to witness the event. The company shared insights on the development of interventional robot technology, clinical research progress, and industrial collaboration, announced the launch of a real-world study, and signed strategic cooperation agreements with Neusoft Medical and Nanwei Kangyou.
From Technological Evolution to Industrial Layout: Company Shares Development Path of Interventional Robots
Subsequently, Hengle Technology CEO Sun Yi delivered a keynote report titled “Image-Guided Percutaneous Interventional Surgical Robots: Review, Current Status, and Prospects.” The report systematically outlined the technological development history, current industry landscape, and future trends of percutaneous interventional surgical robots, while introducing Hengle Technology’s product portfolio and research progress in related fields.
Sun Yi stated that image-guided percutaneous interventional treatment involves multiple key steps, including image acquisition, path planning, puncture navigation, and treatment execution. The development of robotic technology is driving these processes toward greater precision and standardization. In the future, the company will continue to advance product iterations based on clinical needs and explore more clinical application scenarios with partners.
Hengle Technology CEO Sun Yi
Hengle Technology showcases percutaneous puncture surgical robot product
Clinical Research Data Disclosed: Focus on Puncture Accuracy and Operational Efficiency
Clinical application has always been a core focus in the development of interventional robots.
At the meeting, Professor Lu Jian from Zhongda Hospital Southeast University presented a report titled “Interventional Robot System: Evidence-Based Clinical Applications in Percutaneous Puncture,” introducing the pre-market clinical trial results of Hengle Technology’s puncture robot.
According to the data disclosed on-site, robot-assisted puncture demonstrated favorable clinical outcomes across multiple indicators, including first-attempt puncture success rate, puncture accuracy, number of CT scans, and adverse event incidence.
Professor Lu Jian noted that these results provide further evidence-based support for the application of interventional robots in percutaneous puncture scenarios and accumulate experience for the promotion of related technologies in clinical practice.
Professor Lu Jian from Zhongda Hospital Southeast University
From Registered Clinical Trials to Real-World Studies
In addition to sharing clinical trial results, Hengle Technology also held a launch ceremony for a real-world study on interventional surgical robots during the conference.
For medical device products, registered clinical trials primarily verify safety and efficacy under specific conditions, while real-world studies can cover more medical institutions, more physicians, and more complex clinical scenarios, further observing product performance in actual use.
Hengle Technology will subsequently collaborate with more clinical institutions to conduct related research, continuously evaluating the product’s application value in real clinical environments through larger-scale case data and long-term follow-up.
Conference chair Academician Teng Gaojun and attending experts jointly witnessed the launch ceremony.
Launch ceremony of Hengle Technology’s interventional surgical robot real-world study
Two Strategic Collaborations Established: Expanding the Interventional Robot Application Ecosystem
During the conference, Hengle Technology also announced strategic partnerships with Neusoft Medical and Nanwei Kangyou.
Specifically, Hengle Technology and Neusoft Medical will collaborate on image-guided interventional robots. According to their plans, they will jointly explore synergies in technology research and development, clinical research, and market promotion, driving the deep integration of imaging equipment and interventional robot systems.
For interventional robots, imaging equipment is a crucial foundation for preoperative planning and intraoperative navigation. The synergy between robotic systems and imaging platforms is also considered a key direction for improving the precision of interventional treatments.
The other collaboration focuses on tumor ablation scenarios.
Hengle Technology signed a strategic cooperation agreement with Nanwei Kangyou. The two parties plan to integrate puncture navigation technology with microwave ablation equipment resources to jointly advance the development and application of percutaneous interventional microwave ablation surgical robots.
From an industrial perspective, such collaborations help further integrate puncture, navigation, and ablation treatment processes, and are expected to expand the application scenarios of interventional robots in minimally invasive tumor treatments.
Hengle Technology signs strategic cooperation agreements with Neusoft Medical and Nanwei Kangyou
From Single Devices to Comprehensive Solutions
In recent years, sectors such as orthopedic robots and laparoscopic robots have gradually entered the commercialization stage, while percutaneous interventional robots remain in a relatively early phase of development.
Unlike other surgical robots, interventional robots often need to synergize with imaging equipment, navigation systems, and treatment devices. Therefore, competition extends beyond the robot itself to encompass overall solution capabilities and ecosystem building.
Based on the information disclosed at this satellite symposium, whether it is the launch of real-world studies or collaborations with imaging and ablation equipment companies, it reflects the company’s efforts to extend from single-product development to systematic solutions.
Public information shows that Hengle Technology, founded in 2020, has already laid out multiple directions, including percutaneous puncture, transbronchial, and transvascular interventions. In 2025, the company’s first multimodal real-time puncture surgical robot received a Class III medical device registration certificate from the National Medical Products Administration.
With the accumulation of more clinical data and the advancement of industrial collaborations, the application prospects of interventional robots in the minimally invasive treatment of solid tumors will continue to attract industry attention.
In the future, Hengle Technology will continue to advance product iterations based on clinical needs and explore more clinical application scenarios with ecosystem partners.